Bristol-Myers Squibb Company (BMY)
BMY trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/0000014272-26-000004-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BMY on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000014272 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $48.2B |
| Net income | $7.1B |
| Operating income | Not in SEC XBRL data |
| Net margin | 14.6% |
| Operating margin | Operating income not reported |
| Revenue growth | -0.2% |
| Cash | $10.2B |
| Total assets | $90.0B |
| P/E (computed) | 18.2× |
| P/S (computed) | 2.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-29 |
| Cash and burn | $9.6B cash; operating cash flow $2.7B a quarter. | Report 2026-09-30 |
| Shares outstanding | 2,044,085,831 (2026-10-21); 2,035,753,027 a year earlier; 2,034,757,742 three years earlier. | Cover page 2026-10-21 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2025-05-15 |
| Auditor | Deloitte & Touche LLP, Morristown, New Jersey, United States | PCAOB Form AP 2026-02-25 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $2.3M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $13.1B | $2.2B | $4.2B | $9.6B | $43.6B | $50.0B | 10-Q 2026-10-29 |
| Q2 2026 2026-06-30 | $13.0B | $3.3B | $3.4B | $8.7B | $43.9B | $49.2B | 10-Q 2026-07-30 |
| Q1 2026 2026-03-31 | $11.5B | $2.7B | $1.1B | $9.6B | $46.4B | $48.5B | 10-Q 2026-04-30 |
| Q4 2025 2025-12-31 | $12.5B | $1.1B | $2.0B | $10.2B | $47.1B | $48.2B | 10-K 2026-02-11 |
| Q3 2025 2025-09-30 | $12.2B | $2.2B | $6.3B | $15.7B | $53.2B | $48.0B | 10-Q 2026-10-29 |
| Q2 2025 2025-06-30 | $12.3B | $1.3B | $3.9B | $12.6B | $53.7B | $47.7B | 10-Q 2026-07-30 |
| Q1 2025 2025-03-31 | $11.2B | $2.5B | $2.0B | $10.9B | $53.1B | $47.6B | 10-Q 2026-04-30 |
| Q4 2024 2024-12-31 | $12.3B | $72.0M | $4.4B | $10.3B | $51.5B | $48.3B | 10-K 2026-02-11 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-11-07 |
| Latest annual report | 10-K | 2026-02-11 |
| Latest quarterly / interim | 10-Q | 2026-10-29 |
| Latest current report | 8-K | 2026-10-29 |
| Latest proxy | DEFA14A | 2026-04-17 |
Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.1% |
| 1 month | +11.9% |
| 3 months | -1.9% |
| Year to date | +17.6% |
| 1 year | +30.4% |
| From 52-week high | -6.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Incorporated | $537.79 | -0.15% | $136.4B |
| SNY | Sanofi ADS | $48.39 | +0.04% | $118.0B |
| GSK | GSK plc | $50.41 | -0.08% | $102.0B |
| PFE | Pfizer Inc. | $28.86 | -0.10% | $164.5B |
| REGN | Regeneron Pharmaceuticals Inc. | $952.40 | -0.32% | $98.5B |
| NVO | Novo Nordisk A/S | $41.60 | -0.07% | $184.2B |
| ABT | Abbott Laboratories | $107.45 | -0.99% | $186.1B |
| TAK | Takeda Pharmaceutical Company Limited | $21.59 | +0.75% | $68.2B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier